COMPARATIVE STUDY OF OXCARBAZEPINE VERSUS BACLOFEN FOR THE PREVENTION OF RELAPSE IN ALCOHOL DEPENDENCE SYNDROME PATIENTS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i7.54602Keywords:
Oxcarbazepine, Baclofen, mental health, Alcohol Dependence syndromeAbstract
Objective: Alcohol Dependence Syndrome (ADS) is a chronic disorder characterized by both physical and psychological dependence on alcohol, leading to significant health complications. Despite advances in pharmacotherapy and psychological interventions, relapse remains a major challenge. Baclofen and oxcarbazepine have shown potential in reducing relapse rates. This study evaluates the effectiveness of oxcarbazepine versus baclofen in preventing relapse in ADS patients.
Methods: A six-month study was conducted at Sri Ramachandra Institute of Higher Education and Research, involving 59 male patients undergoing treatment for alcohol withdrawal and ADS. Participants were divided into three groups: Group A (Baclofen), Group B (Oxcarbazepine), and Group C (Combination of Baclofen and Oxcarbazepine). Relapse rates and craving levels were assessed using the Alcohol Relapse Risk Scale (ARRS), Penn Alcohol Craving Scale (PACS), and Warning of Relapse (AWARE) scale.
Results: Patients in the combination therapy group (Group C) exhibited a significantly lower relapse rate compared to Groups A and B. Statistically significant improvements in attitude toward treatment were observed across all groups at the first follow-up (45 days), with the most pronounced improvement in Group C. The ARRS, PACS, and AWARE scales confirmed the superior effectiveness of combination therapy in reducing both relapse and cravings.
Conclusion: Alcohol dependence is a treatable disorder, and pharmacotherapy plays a crucial role in managing withdrawal symptoms and preventing relapse. The combination of oxcarbazepine and baclofen appears to be more effective than monotherapy in reducing relapse rates and cravings in ADS patients.
Downloads
References
National Institute on Alcohol Abuse and Alcoholism. Alcohol Use Disorder; 2025. Available from: https://www.niaaa.nih.gov/ publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder [Last accessed on 2025 Feb 26].
World Health Organization. Global Status Report on Alcohol and Health; 2021. Available from: https://www.who.int/publications/i/ item/9789240096745 [Last accessed on 2025 Feb 26].
Raman VV, Singh SK, Jacob R. A study on alcohol use and its related health and social problems in rural Puducherry, India. J Family Med Prim Care. 2016;5(4):678-83. doi: 10.4103/2249-4863.201175
Ehrmann J, Urban O, Dvoran P. Alcohol-related liver diseases. Cent Eur J Public Health. 2019;27 Suppl: S10-4. doi: 10.21101/cejph.a5999, PMID 31901188
Carlson RW, Kumar NN, Wong-McKinstry E, Ayyagari S, Puri N, Jackson FK, et al. Alcohol withdrawal syndrome. Crit Care Clin. 2012;28(4):549-85. doi: 10.1016/j.ccc.2012.07.004, PMID 22998991
Bird RD, Makela EH. Alcohol withdrawal: What is the benzodiazepine of choice? Ann Pharmacother. 1994;28(1):67-71. doi: 10.1177/106002809402800114, PMID 8123967
Cooney G, Heydtmann M, Smith ID. Baclofen and the alcohol withdrawal syndrome-a short review. Front Psychiatry. 2018;9:773. doi: 10.3389/fpsyt.2018.00773, PMID 30723432
De Beaurepaire R. A review of the potential mechanisms of action of baclofen in alcohol use disorder. Front Psychiatry. 2018;9:506. doi: 10.3389/fpsyt.2018.00506, PMID 30459646
Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 2010;16(19):2113-7. doi: 10.2174/138161210791516440, PMID 20482507
Barrons R, Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther. 2010;35(2):153-67. doi: 10.1111/j.1365-2710.2009.01098.x, PMID 20456734
Korlakunta A, Reddy CM. High-risk behavior in patients with alcohol dependence. Indian J Psychiatry. 2019;61(2):125-30. doi: 10.4103/ psychiatry.IndianJPsychiatry_395_17, PMID 30992605
Stang A, Ahrens W, Anastassiou G, Jöckel KH. Phenotypical characteristics, lifestyle, social class and uveal melanoma. Ophthal Epidemiol. 2003;10(5):293-302. doi: 10.1076/opep.10.5.293.17319, PMID 14566630
Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, et al. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(6):609-21. doi: 10.1097/01. chi.0000159135.33706.37, PMID 15908844
Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs. 2005;14(4):371-6. doi: 10.1517/13543784.14.4.371, PMID 15882114
Ministry of Health and Family Welfare, Government of India. Standard Treatment Guidelines for Alcohol Dependence Syndrome; 2016. Available from: https://nhm.gov.in/images/pdf/guidelines/ nrhm/guidelines/stg/alcohol_dependencepdf [Last accessed on 2025 Feb 26].
Pribék IK, Kovács I, Kádár BK, Kovács CS, Richman MJ, Janka Z, et al. Evaluation of the course and treatment of alcohol withdrawal syndrome with the clinical institute withdrawal assessment for alcohol - revised: A systematic review-based meta-analysis. Drug Alcohol Depend. 2021;220:108536. doi: 10.1016/j.drugalcdep.2021.108536, PMID 33503582
Davidoff RA. Alcohol and presynaptic inhibition in an isolated spinal cord preparation. Arch Neurol. 1973;28(1):60-3. doi: 10.1001/ archneur.1973.00490190078011, PMID 4344473
Rose AK, Jones A. Baclofen: Its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. 2018;113(8):1396-406. doi: 10.1111/add.14191, PMID 29479827
Rumgay H, Murphy N, Ferrari P, Soerjomataram I. Alcohol and cancer: Epidemiology and biological mechanisms. Nutrients. 2021;13(9):3173. doi: 10.3390/nu13093173, PMID 34579050
Hartwell EE, Bujarski S, Green R, Ray LA. Convergence between the Penn alcohol Craving Scale and diagnostic interview for the assessment of alcohol craving. Addict Behav Rep. 2019;10:100198. doi: 10.1016/j. abrep.2019.100198, PMID 31304230
Koethe D, Juelicher A, Nolden BM, Braunwarth WD, Klosterkötter J, Niklewski G, et al. Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: A double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res. 2007;31(7):1188-94. doi: 10.1111/j.1530-0277.2007.00419.x, PMID 17511748
Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289-95. doi: 10.1111/j.1530-0277.1999.tb04349.x, PMID 10470970
Ogai Y, Yamashita M, Endo K, Haraguchi A, Ishibashi Y, Kurokawa T, et al. Application of the relapse risk scale to alcohol-dependent individuals in Japan: Comparison with stimulant abusers. Drug Alcohol Depend. 2009;101(1-2):20-6. doi: 10.1016/j.drugalcdep.2008.10.021, PMID 19084356
Miller WR, Harris RJ. A simple scale of Gorski’s warning signs for relapse. J Stud Alcohol. 2000;61(5):759-65. doi: 10.15288/jsa.2000.61.759, PMID 11022817
Singh AP, Sharma AK, Singh TG. Advancements in understanding and managing alcohol withdrawal syndrome: A comprehensive review. Int J Curr Pharm Res. Nov 2024;16(6):6-10. doi: 10.22159/ ijcpr.2024v16i6.5024
Pandhare SP, Gosavi D, Kumar Mishra KK, Sathe HS. Adverse drug reactions of baclofen, naltrexone, and acamprosate in patients having alcohol dependence: A cross-sectional pharmacovigilance study. Asian J Pharm Clin Res. 2024;17(4):111-4. doi: 10.22159/ajpcr.2024. v17i4.49791
Sharma AK, Naruka PS, Soni S, Ranawat MS, Khandelwal M, Aman S. Design and evaluation of fast dissolving tablet of beclofen by using natural (fenugreek powder) superdisintegrant. Int J Curr Pharm Rev Res. 2018;10(3):1-7.
Published
How to Cite
Issue
Section
Copyright (c) 2025 MUGHILAN K, AMIRTHA R.T, B.SRI SNEKHA, VS DEVA PRATHIMAA, KARTHIK THIYAGARAJAN, NATRAJAN SHANMUGASUNDHARAM, RAGESH GURUMOORTHI
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
